>
Switch to:

Sutro Biopharma PE Ratio

: At Loss (As of Today)
View and export this data going back to 2018. Start your Free Trial

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2022-01-28), Sutro Biopharma's share price is $10.39. Sutro Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2021 was $-3.36. Therefore, Sutro Biopharma's PE Ratio for today is At Loss.


The historical rank and industry rank for Sutro Biopharma's PE Ratio or its related term are showing as below:

NAS:STRO' s PE Ratio Range Over the Past 10 Years
Min: At Loss   Med: At Loss   Max: At Loss
Current: At Loss



NAS:STRO's PE Ratio is ranked lower than
99.99% of the 274 Companies
in the Biotechnology industry.

( Industry Median: 29.60 vs. NAS:STRO: At Loss )

Sutro Biopharma's Earnings per Share (Diluted) for the three months ended in Sep. 2021 was $-0.67. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2021 was $-3.36.

As of today (2022-01-28), Sutro Biopharma's share price is $10.39. Sutro Biopharma's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2021 was $-3.36. Therefore, Sutro Biopharma's PE Ratio without NRI for today is At Loss.

Sutro Biopharma's EPS without NRI for the three months ended in Sep. 2021 was $-0.67. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2021 was $-3.36.

During the past 3 years, the average EPS without NRI Growth Rate was 34.60% per year.

During the past 5 years, Sutro Biopharma's highest 3-Year average EPS without NRI Growth Rate was 34.60% per year. The lowest was 34.60% per year. And the median was 34.60% per year.

Sutro Biopharma's EPS (Basic) for the three months ended in Sep. 2021 was $-0.67. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2021 was $-3.36.


Sutro Biopharma PE Ratio Historical Data

The historical data trend for Sutro Biopharma's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sutro Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20
PE Ratio
N/A N/A At Loss At Loss At Loss

Sutro Biopharma Quarterly Data
Dec16 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
PE Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison

For the Biotechnology subindustry, Sutro Biopharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Sutro Biopharma PE Ratio Distribution

For the Biotechnology industry and Healthcare sector, Sutro Biopharma's PE Ratio distribution charts can be found below:

* The bar in red indicates where Sutro Biopharma's PE Ratio falls into.



Sutro Biopharma PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Sutro Biopharma's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=10.39/-3.360
=At Loss

Sutro Biopharma's Share Price of today is $10.39.
Sutro Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.36.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio or PE Ratio (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Sutro Biopharma  (NAS:STRO) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Sutro Biopharma PE Ratio Related Terms

Thank you for viewing the detailed overview of Sutro Biopharma's PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sutro Biopharma Business Description

Sutro Biopharma logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
310 Utah Avenue, Suite 150, South San Francisco, CA, USA, 94080
Sutro Biopharma Inc is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
Executives
Hallam Trevor officer: Chief Scientific Officer PALATIN TECHNOLOGIES, INC. 4C CEDAR BROOK DRIVE CRANBURY NJ 08512
Fitzpatrick Linda A officer: Chief People & Comm. Officer NUVELO, INC. 675 ALMANOR AVENUE SUNNYVALE CA 94085
Shabbir Anik officer: Chief Technical Ops. Officer 310 UTAH AVE, STE. 150 SOUTH SAN FRANCISCO CA 94080
Molina Arturo Md officer: Chief Medical Officer 10990 WILSHIRE BLVD, SUITE 1200 LOS ANGELES CA 90024
Newell William J director, officer: CEO 887 GREAT NORTHERN WAY VANCOUVER A1 V5T 4T5
Albini Edward C officer: CFO and Secretary PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: ALBINI EDWARD C a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Freund John Gordon director 125 UNIVERSITY AVE. C/O SKYLINE VENTURES PALO ALTO CA 94301
Panek James P director C/O VAXGEN INC 1000 MARINA BLVD. #200 BRISBANE CA 94005
Lobacki Joseph M director C/O MICROMET, INC., 9201 CORPORATE BLVD. SUITE 400 ROCKVILLE MD 20850
Dybbs Michael director C/O NEW LEAF VENTURE PARTNERS 1200 PARK PLACE, SUITE 300 SAN MATEO CA 94043
Petree Daniel H director 4350 EXECUTIVE DRIVE SUITE 325 SAN DIEGO CA 92121
Sharp Shalini director C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT NOVATO CA 94949
Matsui Connie director 3030 CALLAN RD SAN DIEGO CA 92121
Janney Daniel director ONE EMBARCADERO CENTER SUITE 3700 SAN FRANCISCO CA 94111
Worsley Stephen officer: Chief Business Officer 310 UTAH AVE., STE. 150 SOUTH SAN FRANCISCO CA 94080

Sutro Biopharma Headlines

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)